XOMA Corporation’s (XOMA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of XOMA Corporation (NASDAQ:XOMA) in a research note published on Tuesday, Marketbeat reports. They currently have a $38.00 price target on the biotechnology company’s stock.

XOMA has been the subject of several other research reports. Zacks Investment Research downgraded XOMA Corporation from a hold rating to a sell rating in a research note on Tuesday, September 26th. ValuEngine upgraded XOMA Corporation from a strong sell rating to a sell rating in a research note on Wednesday, July 12th. Finally, Wedbush restated a hold rating on shares of XOMA Corporation in a research note on Monday, August 14th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of Hold and a consensus target price of $27.33.

XOMA Corporation (NASDAQ:XOMA) traded down 3.14% during midday trading on Tuesday, reaching $22.54. The company’s stock had a trading volume of 92,395 shares. The stock has a 50 day moving average of $19.69 and a 200 day moving average of $10.23. XOMA Corporation has a 52 week low of $3.96 and a 52 week high of $24.92. The firm’s market capitalization is $171.26 million.

ILLEGAL ACTIVITY NOTICE: “XOMA Corporation’s (XOMA) “Buy” Rating Reiterated at HC Wainwright” was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://ledgergazette.com/2017/10/20/xoma-corporations-xoma-buy-rating-reiterated-at-hc-wainwright.html.

A hedge fund recently raised its stake in XOMA Corporation stock. California Public Employees Retirement System grew its position in XOMA Corporation (NASDAQ:XOMA) by 95.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 21,780 shares of the biotechnology company’s stock aft

XOMA has been the subject of several other research reports. Zacks Investment Research downgraded XOMA Corporation from a hold rating to a sell rating in a research note on Tuesday, September 26th. ValuEngine upgraded XOMA Corporation from a strong sell rating to a sell rating in a research note on Wednesday, July 12th. Finally, Wedbush restated a hold rating on shares of XOMA Corporation in a research note on Monday, August 14th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of Hold and a consensus target price of $27.33.

XOMA Corporation (NASDAQ:XOMA) traded down 3.14% during midday trading on Tuesday, reaching $22.54. The company’s stock had a trading volume of 92,395 shares. The stock has a 50 day moving average of $19.69 and a 200 day moving average of $10.23. XOMA Corporation has a 52 week low of $3.96 and a 52 week high of $24.92. The firm’s market capitalization is $171.26 million.

ILLEGAL ACTIVITY NOTICE: “XOMA Corporation’s (XOMA) “Buy” Rating Reiterated at HC Wainwright” was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://ledgergazette.com/2017/10/20/xoma-corporations-xoma-buy-rating-reiterated-at-hc-wainwright.html.

A hedge fund recently raised its stake in XOMA Corporation stock. California Public Employees Retirement System grew its position in XOMA Corporation (NASDAQ:XOMA) by 95.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 21,780 shares of the biotechnology company’s stock after acquiring an additional 10,640 shares during the quarter. California Public Employees Retirement System owned 0.29% of XOMA Corporation worth $123,000 as of its most recent SEC filing. Institutional investors and hedge funds own 32.92% of the company’s stock.

About XOMA Corporation

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.

Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply